-
-
Featured Care Areas
Please check with your insurance provider for more information, and for their most up-to-date list of panel doctors.
^Specialists may qualify to be on the Extended Panel (EP). You may enjoy selected panel benefits depending on your policy and riders.
Dr Chong Kian Tai is a urologist practising in Mount Elizabeth Hospital and Parkway East Hospital, Singapore.
He specialises in the prevention, diagnosis and treatment of prostate cancer, bladder cancer, kidney cancer, testicular cancer and penile cancer.
Dr Chong is proficient in several surgical techniques, such as traditional open surgery, advanced keyhole laparoscopic and endoscopic surgery, as well as the da Vinci Surgical System, a robotic surgical system.
In the treatment of urological cancers, some of the procedures he focuses on include focal therapy for prostate cancer, MRI-ultrasound fusion prostate biopsy, bladder cystoscopy with narrow-band imaging, da Vinci robotic partial nephrectomy, and da Vinci robotic radial prostatectomy.
In the treatment of general urological conditions, he has a focus on less invasive procedures that treat benign prostate hyperplasia, such as UroLift, Rezum, and Prolieve procedures. He is also familiar with retrograde intrarenal surgery, a procedure that uses a flexible ureteroscope to treat small kidney stones by laser stone surgery.
Dr Chong received the full-time clinical Urologic Oncology Fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, USA.
Prior to private practice, he was the consultant, adjunct assistant professor, co-director of urologic oncology and the director of research in the department of urology in Tan Tock Seng Hospital (TTSH). He also managed the urology cancer clinical databases and tissue repository in TTSH. In the Singapore Cancer Society, he was an advisory panel member and helped improve prostate cancer awareness and survivorship.
Dr Chong started molecular research in urologic-oncology on prostate cancer immunology at Seattle, Washington, USA, which was funded by the Southwest Oncology Group, USA, and the Agency for Science, Technology and Research, Singapore. During his time in the Singapore Urological Cancer Consortium, he led several teams in prostate, kidney, bladder and testis cancer research, including projects on precision medicine, biomolecular, nanoparticle, bioimaging and biomedical device studies.
To improve holistic care for urological cancer patients, Dr Chong served as a chairman for the Urology Cancer Multidisciplinary Tumour Board, chairman for the Urology Cancer Support Programme, chairman for Advanced Care Planning Team, and chairman for TTSH’s Prostate Cancer Support Group.
Bachelor of Medicine, Bachelor of Surgery
Member of the Royal College of Surgeons of Edinburgh, UK
Master of Science (Research)